Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: An in-clinic double-blind dose ranging study

Acta Neurologica Scandinavica

Volumn 128, Issue 3, 2013, Pages 166-171

  Grosset, K A ^a   Malek, N ^a   Morgan, F ^b   Grosset, D G ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b VECTURA GROUP PLC   (United Kingdom)

Author keywords

Apomorphine; Motor fluctuations; Parkinson's disease

Indexed keywords

APOMORPHINE; UNCLASSIFIED DRUG; VR 040;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

APOMORPHINE; MOTOR FLUCTUATIONS; PARKINSON'S DISEASE;

ADMINISTRATION, INHALATION; APOMORPHINE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRY POWDER INHALERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84881660134     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12107     Document Type: Article

References (15)

1. Frankel J, Lees A, Kempster P, Stern G. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
2. Dewey R, Maraganore D, Ahlskog J, Matsumoto J. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov Disord 1998;13:782-7.
3. Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37:257-71.
4. Grosset K, Morgan F, Grosset D. Phase IIa randomized double-blind, placebo-controlled, study of inhaled apomorphine in patients with established Parkinson's disease. Poster presentation at the Movement disorder society meeting, Kyoto, Japan, November 2, 2006. Poster Number P1142.
5. Carlson J, Bergstrom D, Walters J. Stimulation of both D1 and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study. Brain Res 1987;400:205-18.
6. Vermeulen R, Drukarch B, Sahadat M, Goosen C, Wolters E, Stoof J. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behaviour of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord 1994;9:664-72.
7. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001;22:93-4.
8. Gancher S, Woodward W, Boucher B, Nutt J. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-8.
9. Deffond D, Durif F, Tournilhac M. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry 1993;56:101-3.
10. Ondo W, Shinawi L, Moore S. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: a single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Mov Disord 2010;25:2724-7.
11. Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol 2003;26:322-6.
12. A double-blind, placebo-controlled, parallel-group, proof of concept trial to assess the tolerability, safety, and efficacy of rotigotine nasal spray for the acute treatment of "OFF" symptoms in subjects with advanced-stage, Idiopathic Parkinson Disease. UCB Inc. ClinicalTrials.gov Identifier: NCT00296192.
13. Stocchi F, Zappia M, Dall'Armi V, et al. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord 2010;25:1881-7.
14. Rascol O, Azulay J, Blin O et al. Orodispersible sublingual piribedil to abort off episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord 2010;25:368-76.
15. Sam E, Jeanjean A, Maloteaux J, Verbeke N. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995;20:27-33.